ALFA Finder| Revenue growth | FY26 revenue down 12% YoY; Q4 down 24% YoY. |
|---|---|
| Margins | EBITDA margins expected to improve with operating leverage. |
| Order book | Orders in place for new US entity Stellon. |
| Demand visibility | Good visibility for H1 FY27; customers derisking supply chains. |
| Management confidence | High for FY27; expect recovery from temporary structural headwinds. |
Growth
FY26 revenue fell 12% YoY; Q4 revenue down 24%. EBITDA margin stood at 35%. API revenue degrew 12%.
Outlook
Guidance for FY27 growth slightly above historical 18% levels. Capex focused on debottlenecking (₹20-30cr per annum).
Risks
Geopolitical instability in Middle East, US tender delays, and CDSCO certification delays affecting European supplies.
Last quarter's promises, checked
Delivered
- Expected Q4 to be stronger → Delivered Q4 revenue down 24% (= MISS)
- API growth volume-driven → Delivered volume-driven growth (= BEAT)
- WHO GMP for injectables → Delivered certification received (= BEAT)
Partly delivered
- Stellon US sales start → Delivered sales started but insignificant (= PARTIAL)
Missed
- Historical 18% baseline growth → Delivered 12% revenue decline (= MISS)
- EBITDA margins at 40% (ex-startups) → Delivered 35% overall (= MISS)
- Middle East tender recoupment → Delivered ongoing geopolitical delay (= MISS)
Earnings Call filed with BSE, NSE: CONCORDBIO. Summary written with AI assistance from the document.
Concord Biotech Ltd: key numbers
- Share price
- ₹599.30
- Market cap
- ₹12,539 Cr
- Revenue (annual)
- ₹1,055 Cr
- Net profit (annual)
- ₹260.9 Cr
- P/E (TTM)
- 44.4×Sector 43.8×
- Promoter holding
- 44.09%+0.01% QoQ
- FII holding
- 7.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Concord Biotech Ltd
All →Concord Biotech Other Announcement
Concord Biotech filed its quarterly shareholding pattern as of 5 November 2026. Promoters hold 39.54% of 20.92 crore shares.
Concord Biotech Bonus Issue
Concord Biotech allotted 10,46,16,204 bonus shares in a 1:1 ratio. Total equity shares rise to 20,92,32,408 after the bonus allotment.
Concord Biotech Earnings Call Transcript: Key Takeaways
Revenue grew 25% YoY driven by API demand, but gross margins contracted 400bps due to rising solvent costs and geopolitical disruptions.
- Call
- Guides 18% growth
Concord Biotech Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue ₹309.1 Cr (+25%) and PAT ₹69.6 Cr (+10%); H1 revenue ₹566.6 Cr (+26%). Margins compressed; Inspira dermatology division launched.
Concord Biotech Bonus Issue
Concord Biotech fixed 4 November 2026 as the record date for a 1:1 bonus issue, with deemed allotment on 5 November 2026. The bonus is subject to statutory and regulatory approvals.
Concord Biotech Q2 FY27 Results: Net Profit ₹69.6 Cr, Up 10.3% YoY
Concord Biotech Ltd reported revenue from operations of ₹309.1 Cr (+25.1% YoY) and net profit of ₹69.6 Cr (+10.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹69.6 Cr · +10.3% YoY